IP Library › Patent Application 13607384
Patent Application
App. No. 13/607,384

POLYPEPTIDES AND ANTIBODIES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/607,384
Abstract

Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand (“TRAIL”) Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds TR-2 from the animal. Antibodies reactive with TR-2 are provided. Also provided are cells producing antibodies reactive with TR-2, pharmaceutical compositions comprising antibodies reactive with TR-2, methods using antibodies reactive with TR-2, and kits comprising antibodies reactive with TR-2. Also provided are methods of decreasing or preventing binding of an antibody to TR-2 by administering such a polypeptide.

Claims (11)

1 - 113 . (canceled)

114 . A method of treating cancer in a patient that has cancer associated with tissue expressing TRAIL receptor-2 (TR-2) comprising administering to the patient a therapeutically effective amount of an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises CDR1 of SEQ ID NO: 30, CDR2 of SEQ ID NO: 30, and CDR3 of SEQ ID NO: 30, and wherein the light chain comprises CDR1 of SEQ ID NO: 64, CDR2 of SEQ ID NO: 64, and CDR3 of SEQ ID NO: 64, and wherein the antibody binds TR-2 and induces cancer cell apoptosis.

115 . The method of claim 114 , wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 30, and wherein the light chain comprises the amino acid sequence of SEQ ID NO: 64.

116 . The method of claim 114 , wherein the antibody is a fully human antibody.

117 . The method of claim 115 , wherein the antibody is a fully human antibody.

118 . The method of claim 114 , wherein the light chain comprises the amino acid sequence of SEQ ID NO: 64.

119 . The method of claim 118 , wherein the antibody is a fully human antibody.

120 . The method of claim 114 , wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 30 in which one of the cysteine residues of SEQ ID NO: 30 is replaced by one non-cysteine residue.

121 . The method of claim 120 , wherein the antibody is a fully human antibody.

122 . The method of claim 120 , wherein the light chain comprises the amino acid sequence of SEQ ID NO: 64.

123 . The method of claim 122 , wherein the antibody is a fully human antibody.